Valence8 US LP Purchases Shares of 18,511 Leap Therapeutics, Inc. (NASDAQ:LPTX)

Valence8 US LP acquired a new position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 18,511 shares of the company’s stock, valued at approximately $48,000. Valence8 US LP owned about 0.07% of Leap Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Marshall Wace LLP boosted its stake in Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after acquiring an additional 58,094 shares in the last quarter. Acadian Asset Management LLC grew its stake in Leap Therapeutics by 349.3% during the 1st quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock worth $750,000 after buying an additional 219,563 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its stake in Leap Therapeutics by 22.2% during the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 284,856 shares of the company’s stock worth $558,000 after buying an additional 51,838 shares during the last quarter. Simplify Asset Management Inc. increased its position in Leap Therapeutics by 67.9% during the second quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock worth $1,237,000 after buying an additional 255,293 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Leap Therapeutics by 111.7% in the first quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after buying an additional 457,904 shares during the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Stock Performance

Shares of LPTX opened at $2.56 on Friday. Leap Therapeutics, Inc. has a fifty-two week low of $1.68 and a fifty-two week high of $5.00. The firm has a 50-day simple moving average of $2.93 and a 200-day simple moving average of $2.57. The company has a market capitalization of $98.09 million, a price-to-earnings ratio of -1.33 and a beta of 0.22.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of Leap Therapeutics in a research report on Friday, November 15th.

Leap Therapeutics Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.